USMLE Step 2 & Step 3 Integration: Advanced
Clinical Scenarios in Multisystem Disease, Complex
Pharmacology, and Diagnostic Reasoning for High-
Stakes Board Examination Preparation a well
detailed exam 2025/2026 graded A+ upgraded !!!
QUESTION 1
A 72-year-old man with a history of hypertension, type 2 diabetes mellitus, and chronic kidney
disease stage 3 presents with a 4-week history of progressive fatigue, anorexia, and a 12-pound
unintentional weight loss. He reports early satiety and intermittent epigastric discomfort. His
medications include lisinopril 40 mg daily, amlodipine 10 mg daily, metformin 1000 mg twice
daily, and atorvastatin 40 mg daily. Physical examination reveals mild conjunctival pallor and a
palpable, nontender, firm mass in the left upper quadrant. Laboratory studies show hemoglobin
9.8 g/dL (normocytic, normochromic), serum creatinine 1.8 mg/dL (baseline 1.2), albumin 3.2
g/dL, and alkaline phosphatase 180 U/L (elevated). Upper endoscopy reveals a large, ulcerated
mass in the gastric body with heaped-up margins; biopsy confirms poorly differentiated
adenocarcinoma with signet-ring cell features. CT of the abdomen and pelvis shows a gastric
mass with local lymphadenopathy and multiple hypodense liver lesions. Which of the following
is the most appropriate next step in managing this patient's renal function before initiating
systemic chemotherapy?
A. Discontinue lisinopril and initiate hydralazine and isosorbide dinitrate for blood pressure
control
B. Discontinue metformin and initiate insulin therapy
C. Obtain a baseline echocardiogram to assess for underlying cardiomyopathy
D. Initiate intravenous hydration with normal saline at 100 mL/hour for 24 hours
E. Perform a percutaneous renal biopsy to evaluate for crescentic glomerulonephritis
Correct Answer: A
,Rationale: This patient has gastric adenocarcinoma with likely metastatic disease to the liver,
and systemic chemotherapy (typically a fluoropyrimidine plus platinum agent) is indicated.
However, he has chronic kidney disease (CKD) with a baseline creatinine of 1.2 mg/dL that has
worsened to 1.8 mg/dL, likely due to prerenal azotemia from decreased oral intake and
malignancy-associated cachexia. Lisinopril, an ACE inhibitor, can further compromise renal
function in the setting of prerenal azotemia by reducing efferent arteriolar tone and glomerular
filtration pressure. Discontinuing lisinopril and using alternative antihypertensives (hydralazine
and isosorbide dinitrate) that do not affect renal hemodynamics is appropriate. Metformin is
not the primary concern in this scenario; although it should be held if renal function worsens
significantly (eGFR <30 mL/min/1.73 m²), the patient's creatinine of 1.8 mg/dL with a baseline
of 1.2 suggests an eGFR likely in the 30-45 range, and metformin is not the immediate cause of
the creatinine elevation. Intravenous hydration may be appropriate, but in the setting of cancer
cachexia and potential volume overload, it should be done cautiously and is not the most
definitive step. Renal biopsy is not indicated without evidence of glomerular disease (no
proteinuria, hematuria, or active sediment). An echocardiogram is not directly relevant to the
renal function management. Thus, discontinuing lisinopril and using alternative
antihypertensives is the most appropriate step to prevent further renal deterioration before
chemotherapy.
QUESTION 2
A 34-year-old woman with a history of systemic lupus erythematosus (SLE) diagnosed 8 years
ago presents with a 3-day history of progressive dyspnea on exertion, nonproductive cough, and
palpitations. She has been noncompliant with her hydroxychloroquine for the past 6 months.
She reports a recent upper respiratory infection 2 weeks ago. On examination, she is tachycardic
(heart rate 112 bpm), tachypneic (respiratory rate 24/min), and afebrile. Jugular venous
pressure is elevated at 14 cm H₂O. Cardiac auscultation reveals a loud S1, a split S2 with an
accentuated pulmonic component, and a grade 2/6 systolic murmur at the left lower sternal
border that increases with inspiration. She has trace bilateral lower extremity edema. An
electrocardiogram shows sinus tachycardia with incomplete right bundle branch block and right
axis deviation. A chest X-ray reveals cardiomegaly with prominence of the pulmonary arteries
and a small right pleural effusion. Laboratory studies show leukopenia (white blood cell count
3,800/µL), thrombocytopenia (platelets 110,000/µL), elevated erythrocyte sedimentation rate
(ESR) of 65 mm/h, and elevated C-reactive protein (CRP) of 4.2 mg/dL. Serum creatinine is 1.3
mg/dL (baseline 0.9), and urinalysis shows proteinuria (2+) and microscopic hematuria (10-15
red blood cells per high-power field). A transthoracic echocardiogram shows a large pericardial
effusion with early signs of diastolic collapse of the right ventricle and a thickened, hypermobile
,mitral valve with moderate regurgitation. Which of the following is the most likely underlying
cause of this patient's acute presentation?
A. Acute pericarditis secondary to viral infection complicated by pericardial effusion with
impending tamponade
B. Libman-Sacks endocarditis with associated pericardial effusion and pulmonary hypertension
C. Acute pulmonary embolism with secondary pulmonary hypertension and pericardial effusion
D. Lupus myocarditis with pericardial effusion and valvular involvement
E. Antiphospholipid antibody syndrome with catastrophic thrombotic vasculopathy
Correct Answer: B
Rationale: This patient with SLE is presenting with multiple cardiac manifestations: a large
pericardial effusion with early hemodynamic compromise, a thickened and hypermobile mitral
valve with regurgitation, and evidence of pulmonary hypertension (accentuated P2, right axis
deviation, incomplete RBBB, and prominence of pulmonary arteries on chest X-ray). The
presence of a thickened, hypermobile mitral valve in SLE is characteristic of Libman-Sacks
endocarditis, a noninfective verrucous endocarditis that can affect any valve but most
commonly the mitral valve. Libman-Sacks endocarditis can cause valvular regurgitation, embolic
phenomena, and can be associated with antiphospholipid antibodies. The pericardial effusion
and possible myocarditis are also known cardiac manifestations of SLE. However, the
combination of pericardial effusion with signs of right heart pressure overload (accentuated P2,
right axis deviation, incomplete RBBB) and a thickened mitral valve points toward Libman-Sacks
endocarditis with associated pulmonary hypertension and pericardial effusion. Acute
pericarditis from viral infection would not explain the mitral valve thickening or the pulmonary
hypertension findings. Pulmonary embolism could cause pulmonary hypertension but would
not explain the pericardial effusion or mitral valve changes. Lupus myocarditis typically presents
with heart failure and arrhythmias, but the valvular findings are more suggestive of Libman-
Sacks. Catastrophic antiphospholipid syndrome would present with multiorgan thrombosis and
is less likely with this subacute presentation. The most appropriate diagnosis is Libman-Sacks
endocarditis with associated pericardial effusion and pulmonary hypertension.
QUESTION 3
A 58-year-old man with a 40-pack-year smoking history and a history of chronic obstructive
pulmonary disease (COPD) on long-term oxygen therapy presents with a 6-week history of
progressive hoarseness, a sensation of a lump in the throat, and difficulty swallowing solids. He
has lost 18 pounds over the past 3 months. Flexible laryngoscopy reveals a large, ulcerated
lesion involving the right true vocal cord, extending to the arytenoid cartilage and pyriform
, sinus. The right vocal cord is fixed in a paramedian position. Biopsy of the lesion demonstrates
moderately differentiated squamous cell carcinoma. A CT scan of the neck and chest with
contrast shows a 3.5 cm primary tumor extending into the paraglottic space, multiple level II
and III cervical lymph nodes on the right (the largest measuring 2.2 cm), and no evidence of
distant metastases. The patient is evaluated by a multidisciplinary tumor board. His
performance status is Eastern Cooperative Oncology Group (ECOG) 1. Which of the following is
the most appropriate definitive treatment approach for this patient?
A. Total laryngectomy with bilateral selective neck dissection followed by postoperative
radiation therapy
B. Concurrent chemoradiation therapy with high-dose cisplatin and intensity-modulated
radiation therapy (IMRT)
C. Induction chemotherapy with docetaxel, cisplatin, and fluorouracil followed by radiation
therapy
D. Partial laryngectomy with ipsilateral neck dissection and adjuvant radiation therapy
E. Definitive radiation therapy with cetuximab as a radiosensitizer
Correct Answer: B
Rationale: This patient has a T3N2bM0 (stage IVA) squamous cell carcinoma of the larynx with
vocal cord fixation (T3), extension into the paraglottic space, and ipsilateral multiple lymph
nodes >6 cm? Actually N2b is multiple ipsilateral nodes, all <6 cm. The standard of care for
advanced laryngeal cancer (stage III/IV) that is resectable but would require a total
laryngectomy is concurrent chemoradiation (CRT) with high-dose cisplatin and radiation
therapy, as established by the RTOG 91-11 trial. This approach offers laryngeal preservation
without compromising survival compared to total laryngectomy. The patient has good
performance status (ECOG 1) and normal renal function, making him a candidate for cisplatin-
based chemotherapy. Total laryngectomy would be appropriate if organ preservation fails, but it
is not the first-line definitive approach. Induction chemotherapy followed by radiation is an
alternative but has not been shown to be superior to concurrent CRT and is associated with
more toxicity. Partial laryngectomy is not appropriate for T3 disease with vocal cord fixation and
nodal involvement. Definitive radiation with cetuximab is an option for patients who cannot
tolerate cisplatin (e.g., renal dysfunction, hearing loss), but this patient has no contraindications
to cisplatin. Therefore, concurrent chemoradiation with cisplatin and IMRT is the most
appropriate definitive treatment approach.
QUESTION 4
Clinical Scenarios in Multisystem Disease, Complex
Pharmacology, and Diagnostic Reasoning for High-
Stakes Board Examination Preparation a well
detailed exam 2025/2026 graded A+ upgraded !!!
QUESTION 1
A 72-year-old man with a history of hypertension, type 2 diabetes mellitus, and chronic kidney
disease stage 3 presents with a 4-week history of progressive fatigue, anorexia, and a 12-pound
unintentional weight loss. He reports early satiety and intermittent epigastric discomfort. His
medications include lisinopril 40 mg daily, amlodipine 10 mg daily, metformin 1000 mg twice
daily, and atorvastatin 40 mg daily. Physical examination reveals mild conjunctival pallor and a
palpable, nontender, firm mass in the left upper quadrant. Laboratory studies show hemoglobin
9.8 g/dL (normocytic, normochromic), serum creatinine 1.8 mg/dL (baseline 1.2), albumin 3.2
g/dL, and alkaline phosphatase 180 U/L (elevated). Upper endoscopy reveals a large, ulcerated
mass in the gastric body with heaped-up margins; biopsy confirms poorly differentiated
adenocarcinoma with signet-ring cell features. CT of the abdomen and pelvis shows a gastric
mass with local lymphadenopathy and multiple hypodense liver lesions. Which of the following
is the most appropriate next step in managing this patient's renal function before initiating
systemic chemotherapy?
A. Discontinue lisinopril and initiate hydralazine and isosorbide dinitrate for blood pressure
control
B. Discontinue metformin and initiate insulin therapy
C. Obtain a baseline echocardiogram to assess for underlying cardiomyopathy
D. Initiate intravenous hydration with normal saline at 100 mL/hour for 24 hours
E. Perform a percutaneous renal biopsy to evaluate for crescentic glomerulonephritis
Correct Answer: A
,Rationale: This patient has gastric adenocarcinoma with likely metastatic disease to the liver,
and systemic chemotherapy (typically a fluoropyrimidine plus platinum agent) is indicated.
However, he has chronic kidney disease (CKD) with a baseline creatinine of 1.2 mg/dL that has
worsened to 1.8 mg/dL, likely due to prerenal azotemia from decreased oral intake and
malignancy-associated cachexia. Lisinopril, an ACE inhibitor, can further compromise renal
function in the setting of prerenal azotemia by reducing efferent arteriolar tone and glomerular
filtration pressure. Discontinuing lisinopril and using alternative antihypertensives (hydralazine
and isosorbide dinitrate) that do not affect renal hemodynamics is appropriate. Metformin is
not the primary concern in this scenario; although it should be held if renal function worsens
significantly (eGFR <30 mL/min/1.73 m²), the patient's creatinine of 1.8 mg/dL with a baseline
of 1.2 suggests an eGFR likely in the 30-45 range, and metformin is not the immediate cause of
the creatinine elevation. Intravenous hydration may be appropriate, but in the setting of cancer
cachexia and potential volume overload, it should be done cautiously and is not the most
definitive step. Renal biopsy is not indicated without evidence of glomerular disease (no
proteinuria, hematuria, or active sediment). An echocardiogram is not directly relevant to the
renal function management. Thus, discontinuing lisinopril and using alternative
antihypertensives is the most appropriate step to prevent further renal deterioration before
chemotherapy.
QUESTION 2
A 34-year-old woman with a history of systemic lupus erythematosus (SLE) diagnosed 8 years
ago presents with a 3-day history of progressive dyspnea on exertion, nonproductive cough, and
palpitations. She has been noncompliant with her hydroxychloroquine for the past 6 months.
She reports a recent upper respiratory infection 2 weeks ago. On examination, she is tachycardic
(heart rate 112 bpm), tachypneic (respiratory rate 24/min), and afebrile. Jugular venous
pressure is elevated at 14 cm H₂O. Cardiac auscultation reveals a loud S1, a split S2 with an
accentuated pulmonic component, and a grade 2/6 systolic murmur at the left lower sternal
border that increases with inspiration. She has trace bilateral lower extremity edema. An
electrocardiogram shows sinus tachycardia with incomplete right bundle branch block and right
axis deviation. A chest X-ray reveals cardiomegaly with prominence of the pulmonary arteries
and a small right pleural effusion. Laboratory studies show leukopenia (white blood cell count
3,800/µL), thrombocytopenia (platelets 110,000/µL), elevated erythrocyte sedimentation rate
(ESR) of 65 mm/h, and elevated C-reactive protein (CRP) of 4.2 mg/dL. Serum creatinine is 1.3
mg/dL (baseline 0.9), and urinalysis shows proteinuria (2+) and microscopic hematuria (10-15
red blood cells per high-power field). A transthoracic echocardiogram shows a large pericardial
effusion with early signs of diastolic collapse of the right ventricle and a thickened, hypermobile
,mitral valve with moderate regurgitation. Which of the following is the most likely underlying
cause of this patient's acute presentation?
A. Acute pericarditis secondary to viral infection complicated by pericardial effusion with
impending tamponade
B. Libman-Sacks endocarditis with associated pericardial effusion and pulmonary hypertension
C. Acute pulmonary embolism with secondary pulmonary hypertension and pericardial effusion
D. Lupus myocarditis with pericardial effusion and valvular involvement
E. Antiphospholipid antibody syndrome with catastrophic thrombotic vasculopathy
Correct Answer: B
Rationale: This patient with SLE is presenting with multiple cardiac manifestations: a large
pericardial effusion with early hemodynamic compromise, a thickened and hypermobile mitral
valve with regurgitation, and evidence of pulmonary hypertension (accentuated P2, right axis
deviation, incomplete RBBB, and prominence of pulmonary arteries on chest X-ray). The
presence of a thickened, hypermobile mitral valve in SLE is characteristic of Libman-Sacks
endocarditis, a noninfective verrucous endocarditis that can affect any valve but most
commonly the mitral valve. Libman-Sacks endocarditis can cause valvular regurgitation, embolic
phenomena, and can be associated with antiphospholipid antibodies. The pericardial effusion
and possible myocarditis are also known cardiac manifestations of SLE. However, the
combination of pericardial effusion with signs of right heart pressure overload (accentuated P2,
right axis deviation, incomplete RBBB) and a thickened mitral valve points toward Libman-Sacks
endocarditis with associated pulmonary hypertension and pericardial effusion. Acute
pericarditis from viral infection would not explain the mitral valve thickening or the pulmonary
hypertension findings. Pulmonary embolism could cause pulmonary hypertension but would
not explain the pericardial effusion or mitral valve changes. Lupus myocarditis typically presents
with heart failure and arrhythmias, but the valvular findings are more suggestive of Libman-
Sacks. Catastrophic antiphospholipid syndrome would present with multiorgan thrombosis and
is less likely with this subacute presentation. The most appropriate diagnosis is Libman-Sacks
endocarditis with associated pericardial effusion and pulmonary hypertension.
QUESTION 3
A 58-year-old man with a 40-pack-year smoking history and a history of chronic obstructive
pulmonary disease (COPD) on long-term oxygen therapy presents with a 6-week history of
progressive hoarseness, a sensation of a lump in the throat, and difficulty swallowing solids. He
has lost 18 pounds over the past 3 months. Flexible laryngoscopy reveals a large, ulcerated
lesion involving the right true vocal cord, extending to the arytenoid cartilage and pyriform
, sinus. The right vocal cord is fixed in a paramedian position. Biopsy of the lesion demonstrates
moderately differentiated squamous cell carcinoma. A CT scan of the neck and chest with
contrast shows a 3.5 cm primary tumor extending into the paraglottic space, multiple level II
and III cervical lymph nodes on the right (the largest measuring 2.2 cm), and no evidence of
distant metastases. The patient is evaluated by a multidisciplinary tumor board. His
performance status is Eastern Cooperative Oncology Group (ECOG) 1. Which of the following is
the most appropriate definitive treatment approach for this patient?
A. Total laryngectomy with bilateral selective neck dissection followed by postoperative
radiation therapy
B. Concurrent chemoradiation therapy with high-dose cisplatin and intensity-modulated
radiation therapy (IMRT)
C. Induction chemotherapy with docetaxel, cisplatin, and fluorouracil followed by radiation
therapy
D. Partial laryngectomy with ipsilateral neck dissection and adjuvant radiation therapy
E. Definitive radiation therapy with cetuximab as a radiosensitizer
Correct Answer: B
Rationale: This patient has a T3N2bM0 (stage IVA) squamous cell carcinoma of the larynx with
vocal cord fixation (T3), extension into the paraglottic space, and ipsilateral multiple lymph
nodes >6 cm? Actually N2b is multiple ipsilateral nodes, all <6 cm. The standard of care for
advanced laryngeal cancer (stage III/IV) that is resectable but would require a total
laryngectomy is concurrent chemoradiation (CRT) with high-dose cisplatin and radiation
therapy, as established by the RTOG 91-11 trial. This approach offers laryngeal preservation
without compromising survival compared to total laryngectomy. The patient has good
performance status (ECOG 1) and normal renal function, making him a candidate for cisplatin-
based chemotherapy. Total laryngectomy would be appropriate if organ preservation fails, but it
is not the first-line definitive approach. Induction chemotherapy followed by radiation is an
alternative but has not been shown to be superior to concurrent CRT and is associated with
more toxicity. Partial laryngectomy is not appropriate for T3 disease with vocal cord fixation and
nodal involvement. Definitive radiation with cetuximab is an option for patients who cannot
tolerate cisplatin (e.g., renal dysfunction, hearing loss), but this patient has no contraindications
to cisplatin. Therefore, concurrent chemoradiation with cisplatin and IMRT is the most
appropriate definitive treatment approach.
QUESTION 4
